Amount Raised
$10 Million
Round Type
Series A
BostonBiotechnologyHealth CareTherapeuticsDescription
Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel TNF Superfamily antagonist antibodies, announced today that the company has completed $10 M Series A/A1 preferred stock financing. Investors in the Series A preferred stock financing include BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments. Funds will support the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates
Quick answer
Boston Immune Technologies and Therapeutics (BITT) raised $10 Million in a Series A round, dated March 17, 2021. Boston Immune Technologies and Therapeutics (BITT) is based in Boston, Massachusetts, United States.
- How much did Boston Immune Technologies and Therapeutics (BITT) raise?
- Boston Immune Technologies and Therapeutics (BITT) raised $10 Million in a Series A round on March 17, 2021.
- What does Boston Immune Technologies and Therapeutics (BITT) do?
- BITT is a Boston, MA-based company developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease based on the..
- Where is Boston Immune Technologies and Therapeutics (BITT) based and how big is it?
- Boston Immune Technologies and Therapeutics (BITT) is based in Boston, Massachusetts, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Boston Immune Technologies and Therapeutics (BITT) that raised within 45 days of this round, from Fundz verified event records.
- Revelation Biosciences raised $4.4M (Series A) on April 22, 2021.
- RxMP Therapeutics raised $1M (Seed) on April 21, 2021.
- Os Therapies raised $6M (Series A) on April 20, 2021.
- Liquidia raised $22M on April 16, 2021.
- Alchemab Therapeutics raised $78M (Series A) on April 15, 2021.
- CUREMARK LLC raised $1.5M (Seed) on April 14, 2021.
Who to call at Boston Immune Technologies and Therapeutics (BITT), and when
A new round usually means Boston Immune Technologies and Therapeutics (BITT) is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Boston Immune Technologies and Therapeutics (BITT) raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Boston Immune Technologies and Therapeutics (BITT), from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Boston Immune Technologies and Therapeutics (BITT). With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Boston Immune Technologies and Therapeutics (BITT) raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBoston Immune Technologies and Therapeutics (BITT) raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.